High-density lipoprotein as a therapeutic target: a systematic review.
暂无分享,去创建一个
[1] Diederick E Grobbee,et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial , 2007, The Lancet.
[2] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[3] F. Zimetti,et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits Published, JLR Papers in Press, February 26, 2007. , 2007, Journal of Lipid Research.
[4] Y. Ohashi,et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. , 2007, Archives of internal medicine.
[5] E. Rimm,et al. Alcohol and Coronary Heart Disease: Drinking Patterns and Mediators of Effect , 2007 .
[6] D. Grobbee,et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .
[7] Colin Berry,et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.
[8] Jean-Claude Tardif,et al. Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.
[9] S. Nissen,et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. , 2007, JAMA.
[10] Paul Schoenhagen,et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.
[11] V. Burke,et al. A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial. , 2007, Journal of clinical epidemiology.
[12] A. Tall,et al. The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[13] P. Shah,et al. Emerging strategies for increasing high-density lipoprotein. , 2006, The American journal of cardiology.
[14] D. Rader,et al. Abstract 1496: Oral Administration of the Apolipoprotein A-I Mimetic Peptide D-4F in Humans with CHD Improves HDL Anti-Inflammatory Function After a Single Dose , 2006 .
[15] Allen J. Taylor,et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.
[16] S. Reddy,et al. Mechanisms of Disease: proatherogenic HDL—an evolving field , 2006, Nature Clinical Practice Endocrinology &Metabolism.
[17] G. Fonarow,et al. High-density lipoprotein: Is it always atheroprotective? , 2006, Current atherosclerosis reports.
[18] P. Barter,et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. , 2006, Journal of the American College of Cardiology.
[19] A. Tall,et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.
[20] G. O'neill,et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[21] Carl J Pepine,et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. , 2006, The New England journal of medicine.
[22] F Xavier Pi-Sunyer,et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.
[23] K. Rye,et al. What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[24] C. Roberts,et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. , 2004, Journal of applied physiology.
[25] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[26] E. Topol,et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.
[27] J. Després,et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.
[28] K. Watson,et al. High-density lipoprotein function recent advances. , 2005, Journal of the American College of Cardiology.
[29] Fernando Costa,et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.
[30] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[31] Serkalem Demissie,et al. Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[32] A. Császár. Hypertriglyceridemia, the coronary heart disease risk marker "solved". , 2005, Acta physiologica Hungarica.
[33] J. Buse,et al. Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes , 2005 .
[34] S. Reddy,et al. Apolipoprotein A-I mimetic peptides. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[35] D. Rader,et al. New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.
[36] S. Reddy,et al. The double jeopardy of HDL , 2005, Annals of medicine.
[37] M. Trip,et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. , 2005, The American journal of cardiology.
[38] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[39] P. Linsel-Nitschke,et al. HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.
[40] J. Burgess,et al. Phosphatidylinositol increases HDL-C levels in humans Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400438-JLR200 , 2005, Journal of Lipid Research.
[41] R. Hoffmann,et al. Influence of glycemic load on HDL cholesterol in youth. , 2005, The American journal of clinical nutrition.
[42] B. Ansell. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia , 2005, Current atherosclerosis reports.
[43] A. Gotto,et al. A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events , 2005, Annals of Internal Medicine.
[44] Jeannie K. Lee,et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.
[45] Michael Kinter,et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.
[46] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[47] Meyers Cd,et al. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. , 2004 .
[48] S. Reddy,et al. Oral D-4F Causes Formation of Pre-βHigh-Density Lipoprotein and Improves High-Density Lipoprotein–Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E–Null Mice , 2004, Circulation.
[49] G. Assmann,et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* , 2004, Current medical research and opinion.
[50] A. Gotto,et al. HDL Cholesterol and Protective Factors in Atherosclerosis , 2004, Circulation.
[51] J. Yano,et al. A Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.
[52] Aldons J Lusis,et al. Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.
[53] A. Tall,et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly Published, JLR Papers in Press, February 16, 2004. DOI 10.1194/jlr.M300520-JLR200 , 2004, Journal of Lipid Research.
[54] D. Rader,et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.
[55] T. Sand,et al. Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[56] A. Zwinderman,et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) , 2004, European journal of clinical investigation.
[57] S. Haffner. Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.
[58] Shirin Rahmani,et al. Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.
[59] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[60] P. Drake,et al. Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes , 2003 .
[61] J. Tayek,et al. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[62] S. Deakin,et al. Simvastatin Modulates Expression of the PON1 Gene and Increases Serum Paraoxonase: A Role for Sterol Regulatory Element–Binding Protein-2 , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[63] M. Navab,et al. Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E–Null Mice , 2003, Circulation.
[64] T. Fukui,et al. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. , 2003, Preventive medicine.
[65] Elinor Miller,et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.
[66] R. Mensink,et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.
[67] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[68] H. Mabuchi,et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. , 2002, Clinical science.
[69] T. Meade,et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.
[70] W. Kraus,et al. Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.
[71] E. Schaefer,et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. , 2002, Atherosclerosis.
[72] S. Grundy,et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.
[73] A. Zwinderman,et al. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.
[74] M. McGovern,et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. , 2002, The American journal of cardiology.
[75] R. Lallone,et al. Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol , 2002, Circulation.
[76] W. Dietz,et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.
[77] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[78] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[79] Jan Nilsson,et al. Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.
[80] A. Sharrett,et al. Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.
[81] B. Staels,et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.
[82] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.
[84] D. Hunninghake,et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. , 2000, JAMA.
[85] M. Khurana,et al. Lipid profile in smokers and tobacco chewers--a comparative study. , 2000, The Journal of the Association of Physicians of India.
[86] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[87] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[88] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[89] R. Klein,et al. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. , 1999, JAMA.
[90] K. Gould,et al. Intensive lifestyle changes for reversal of coronary heart disease. , 1998, JAMA.
[91] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[92] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[93] M. Hope,et al. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. , 1998, Biochimica et biophysica acta.
[94] M. Nieminen,et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.
[95] W. Harris,et al. n-3 fatty acids and serum lipoproteins: animal studies. , 1997, The American journal of clinical nutrition.
[96] A. Tall,et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.
[97] A. Hamsten,et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.
[98] R. Krauss,et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.
[99] W. Willett,et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. , 1993, The New England journal of medicine.
[100] A. Tall. Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.
[101] W. Mack,et al. Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.
[102] A. Dattilo,et al. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.
[103] S. Azen,et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. , 1991, Circulation.
[104] S. Azen,et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. , 1990, JAMA.
[105] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[106] D. Gordon,et al. High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.
[107] G. Rosenhamer,et al. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.
[108] C. Fielding,et al. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. , 1988, Biochemistry.
[109] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[110] P. Weisweiler,et al. Plasma lipoproteins and lipase and lecithin:cholesterol acyltransferase activities in obese subjects before and after weight reduction. , 1987, The Journal of clinical endocrinology and metabolism.
[111] D H Blankenhorn,et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.
[112] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[113] P. Wilson,et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.
[114] D Kromhout,et al. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. , 1985, The New England journal of medicine.
[115] D. Grafnetter,et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.
[116] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.